OPEN ACCESS Freely available online

Molecular Pathology and Biochemistry

Commentary

Targeted Therapies Based on Molecular Pathway Analysis

Michael O'Connor*

Department of Pathology, Trinity College Dublin, Dublin, Ireland.

ABOVE THE STUDY

Targeted therapies based on molecular pathway analysis represent one of the most significant advances in modern medicine, fundamentally changing how we approach disease treatment, particularly in oncology and other complex disorders. In my opinion, this shift from broadly cytotoxic approaches to highly specific pathway-directed interventions marks a transition toward truly rational and mechanism-based therapy, where treatment decisions are guided by the underlying biology of disease rather than its anatomical or histological appearance alone.

At the core of this therapeutic strategy is the understanding that diseases, especially cancer, are driven by dysregulated molecular pathways rather than isolated genetic mutations. Cellular processes such as proliferation, apoptosis, angiogenesis, and metabolism are controlled by interconnected signaling networks. When key nodes within these networks become altered through mutations, overexpression, or epigenetic changes they create dependencies that can be therapeutically exploited. In my view, this concept of "pathway addiction" is central to the success of targeted therapies.

One of the most well-established examples is the targeting of the Epidermal Growth Factor Receptor (EGFR) pathway in cancer. Mutations or overactivation of EGFR lead to uncontrolled cell proliferation in several tumor types. Small molecule inhibitors and monoclonal antibodies targeting EGFR have demonstrated significant clinical efficacy in selected patient populations. Similarly, targeting downstream signaling pathways such as RAS-RAF-MEK-ERK and PI3K-AKT-mTOR has provided additional therapeutic opportunities. These interventions highlight how pathway analysis can directly inform drug development and clinical decision-making.

Another important example is the use of BCR-ABL tyrosine kinase inhibitors in Chronic Myeloid Leukemia (CML). The identification of the Philadelphia chromosome and its associated fusion protein revolutionized treatment by enabling precise targeting of a single aberrant signaling molecule. In my opinion, this represents one of the clearest successes of pathway-driven therapy, demonstrating how molecular understanding can transform a previously fatal disease into a manageable chronic condition.

Beyond oncology, targeted therapies are increasingly being applied in autoimmune and inflammatory diseases. For example, inhibition of Tumor Necrosis Factor-alpha (TNF-α) has proven highly effective in conditions such as rheumatoid arthritis and inflammatory bowel disease. Similarly, targeting interleukins and Janus kinase (JAK) signaling pathways has expanded therapeutic options for patients with immune-mediated disorders. These approaches underscore the broader applicability of pathway-based interventions beyond cancer.

A key advantage of targeted therapies is their ability to improve treatment specificity while reducing systemic toxicity. Conventional chemotherapies often affect rapidly dividing normal cells, leading to significant side effects. In contrast, targeted agents aim to selectively inhibit disease-driving pathways, thereby sparing normal cellular functions. However, in my opinion, this selectivity is not absolute, and off-target effects remain a significant clinical challenge.

One of the major limitations of targeted therapy is the development of drug resistance. Tumor cells, in particular, exhibit remarkable adaptability by activating alternative signaling pathways, acquiring secondary mutations, or undergoing phenotypic changes such as epithelial-to-mesenchymal transition. This metabolic and signaling plasticity allows them to bypass inhibited pathways and continue proliferating. As a result, single-agent targeted therapies often lose effectiveness over time.

To address this issue, combination therapies targeting multiple nodes within the same or parallel pathways are being explored. For example, dual inhibition of EGFR and MET or simultaneous targeting of PI3K and MEK pathways has shown promise in overcoming resistance mechanisms. In my view, combination strategies represent a more realistic approach to long-term disease control, as they account for the redundancy and adaptability of biological systems.

Another emerging dimension of targeted therapy is the integration of molecular diagnostics and real-time pathway

Correspondence to Michael O'Connor, Department of Pathology, Trinity College Dublin, Dublin, Ireland. E-mail: michael.oconnor@tcd.ie

Received: 17-Nov-2025, Manuscript No. JMPB-25-41772; **Editor assigned:** 19-Nov-2025, PreQC No. JMPB-25-41772 (PQ); **Reviewed:** 03-Dec-2025, QC No. JMPB-25-41772; **Revised:** 10-Dec-2025, Manuscript No. JMPB-25-41772 (R); **Published:** 17-Dec-2025. DOI: 10.35248/jmpb.25.6.233.

Citation: Connor M (2025), Targeted Therapies Based on Molecular Pathway Analysis. J Mol Pathol Biochem.6:233.

Copyright: © 2025 Connor M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

monitoring. Techniques such as next-generation sequencing, proteomics, and liquid biopsy allow clinicians to identify actionable mutations and monitor pathway activity dynamically. This enables a more personalized approach to treatment, where therapies can be adjusted based on evolving molecular profiles.

Despite these advances, several challenges remain. One major issue is the complexity of signaling networks, which are highly interconnected and context-dependent. Inhibiting one pathway can unintentionally activate compensatory mechanisms, leading to unpredictable outcomes. Additionally, interpatient variability in genetic and epigenetic landscapes makes it difficult to design universally effective targeted therapies.

Cost and accessibility also remain important concerns. Many targeted therapies are expensive, limiting their availability in resource-constrained settings. In my opinion, addressing these disparities is essential for ensuring equitable access to precision medicine.

In conclusion, targeted therapies based on molecular pathway analysis represent a major advancement in modern medical treatment. In my view, their success lies in their ability to translate molecular insights into clinically effective interventions. While challenges such as resistance, complexity, and accessibility remain, continued progress in systems biology, molecular diagnostics, and drug development is likely to further enhance the effectiveness and applicability of pathway-based therapeutic strategies in the future.